Celgene Bolsters Pipeline With Avila Acquisition

Celgene will acquire the Massachusetts biotech for $350 million upfront plus $575 million in potential milestones related to Avila’s lead compound as well as other compounds to emerge from its technology platform.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet